February 28, 2017 / 18:01 IST
Management cuts FY17 revenue guidance to 12% (15% earlier), as domestic agrichemsegment (40% of revenue) was hit by weak Southern monsoon and cash crunch. Likely to report higher growth in FY18 (our expectation at 17.5%), as CSM segment continues traction and domestic segment recovers.
Outlook
Recovery in global agrichem market or success in pharma CSM will materially improve PI’s earnings, margins and return ratios, as share of CSM (high-margin) in overall revenue mix increases. Maintain BUY with TP of Rs 1,000 (27x FY18E EPS).
For all recommendations, click here Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions. 
Read More
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
